bluebird bio Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon. Thanks, everyone, for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the bluebird team with us. So we have Andrew Obenshain, CEO; and we have Tom Klima, Chief Commercial and Operating Officer.
Questions & Answers
So to start here, it's been a really busy time for you guys given the launch of 2 drugs and 2 different indications here with the potential for a third in sickle cell to come. So just help us understand maybe starting with ZYNTEGLO, and we can go through these programs. But it's approved in August of last year, and the first patient was infused in April. So can you just walk us through your launch strategy and how it's -- if it has changed at all during the period and the process and where bottlenecks have been or -- and where they've maybe been alleviated and kind of where you stand today with that?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
